ClinicalTrials.gg
RecruitingNCT06293417ENSEMBLEUpdated Aug 27, 2024

To Assess With Ezefeno Tab. in Patients With Dyslipidemia and T2DM

An interventional study of Ezetimibe/fenofibrate (Ezefeno) and moderate-intensity statin and Dose escalation of moderate-intensity statin in T2DM (Type 2 Diabetes Mellitus) and Dyslipidemias, sponsored by Korea University Anam Hospital. Recruiting at 1 site in Korea, Republic of. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2024-08-27.

Sponsored by Korea University Anam Hospital · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Mar 2024; still recruiting 2 years 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
3,958
Allocation
Randomized
Ages
19 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 571 studies in Diabetes Mellitus, Type 2 with a site in Korea, Republic of — 70 open to participants now, 84 under way, 26 of them phase 3. Diabetes Mellitus, Type 2 · Korea, Republic of.

Planned enrollment
25th of 493
3,958 · median 174
Started
2024
with 35 others
No phase
48 of 571
8 open now
Primary completion
2027-02
later than 50 of 83 live
Registered
480th of 571
by date

Among the 571 studies in Diabetes Mellitus, Type 2 with a site in Korea, Republic of, this one is the 25th largest by planned enrollment of the 493 interventional ones that give a count, is one of 36 that started in 2024, is one of 48 with no phase, reaches primary completion later than 50 of the 83 other live ones, and was the 480th registered.

Diabetes Mellitus, Type 2

10,403 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

70 of the 571 studies in Diabetes Mellitus, Type 2 with a site in Korea, Republic of are open now. Recruiting first, the newest first:

65 more — sign in →

All 70 open studies →

A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →

Who these studies take

Of the 882 Diabetes Mellitus, Type 2 studies recruiting now, 372 (42%) set no upper age limit and 384 (44%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.

This study: 19 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 571 studies in Diabetes Mellitus, Type 2 with a site in Korea, Republic of, or all of them as a file.
02

Study summary

The goal of this Randomized controlled trials is to assess in the long term efficacy and safety of ezefeno. The primary endpoint are:

  • major adverse cardiovascular events within 48 months of the trial duration
  • microvascular events within 48 months of the trial duration
Read the detailed description

A prospective, randomized, open-label, parallel, multicenter, active-drug-controlled clinical trial to assess the long-term efficacy and safety of Combined Therapy with Ezefeno Tab. in patients with dyslipidemia who do not achieve adequate control of Non-HDL-C levels even with Moderate-intensity monotherapy.

03

Conditions studied

  • T2DM (Type 2 Diabetes Mellitus)
  • Dyslipidemias
04

Who can participate

Ages eligible
19 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with type 2 diabetes diagnosed by American Diabetes Association criteria
  • Age ≥ 19 years
  • Non-HDL-C ≥100 mg/dL, TG ≥200, \<500 mg/dL on moderate-intensity statins
  • with cardiovascular risk factor

Exclusion criteria

Exclusion Criteria:

  • Pregnant or breastfeeding women
  • Uncontrolled hyperglycemia(more than 12.0% for Subject treated with anti-diabetic treatment.)
  • Patient with myopathy and rhabdomyolysis
  • /ALT more than 3
  • Clinical evidence of genetic disorders such as galactose intolerance, Lapp lactose deficiency, and/or glucose-galactose malabsorption
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
3,958 participants (estimated)

Study arms

  • Experimental
    Treatment group

    Ezetimibe/fenofibrate (Ezefeno) and moderate-intensity statin

    Drug: Ezetimibe/fenofibrate (Ezefeno) and moderate-intensity statin

  • Active comparator
    Control group

    Dose escalation of moderate-intensity statin

    Drug: Dose escalation of moderate-intensity statin

Interventions

  • DrugEzetimibe/fenofibrate (Ezefeno) and moderate-intensity statin

    Treatment group

  • DrugDose escalation of moderate-intensity statin

    Control group

06

What researchers measure

Primary outcomes

  1. major adverse cardiovascular events and diabetic microvascular events for 48 months

    major adverse cardiovascular events and diabetic microvascular events for 48 months

    Time frame: 48month from baseline

Secondary outcomes

  1. proportion of patients achieving Non-HDL-C less than 100mg/dL

    proportion of patients achieving Non-HDL-C less than 100mg/dL

    Time frame: 48month from baseline

  2. proportion of patients achieving LDL less than 70mg/dL

    proportion of patients achieving LDL less than 70mg/dL

    Time frame: 48month from baseline

  3. change in Non-HDL-C at 48month from baseline

    change in Non-HDL-C at 48month from baseline

    Time frame: 48month from baseline

  4. change in LDL at 48month from baseline

    change in LDL at 48month from baseline

    Time frame: 48month from baseline

  5. change in HDL-C at 48month from baseline

    change in HDL-C at 48month from baseline

    Time frame: 48month from baseline

  6. change in TG at 48month from baseline

    change in TG at 48month from baseline

    Time frame: 48month from baseline

  7. change in LDL-C/HDL-C ratio at 48month from baseline

    change in LDL-C/HDL-C ratio at 48month from baseline

    Time frame: 48month from baseline

  8. change in TC/HDL-C ratio at 48month from baseline

    change in TC/HDL-C ratio at 48month from baseline

    Time frame: 48month from baseline

07

Study locations

1 of 1 sites recruiting
  • Korea University Anam Hospital
    Seoul, Korea, Republic of
    Recruiting
    • Sin Gon Kim, MD · Contact
    • Sin Gon Kim, MD, PHD · Principal investigator
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2024 (actual). Primary completion is estimated for Feb 2027, 35 months after the start.

Of 2,078 non-industry interventional studies with no phase under Diabetes Mellitus, Type 2, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 40. This study's planned 35 months is above that.

Counting every sponsor, half of 2,255 studies reached it within 21 months; a quarter within 10 and three quarters within 39.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 19, 2024
First posted
Mar 5, 2024
StartActual
Mar 1, 2024
Primary completionEst.
Feb 1, 2027
CompletionEst.
Feb 1, 2027
Last update
Aug 27, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 27, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06293417
Responsible party
Sin Gon Kim (professor, Korea University Anam Hospital) — Principal investigator
First posted
Mar 5, 2024
Start date
Mar 1, 2024
Primary completion
Feb 1, 2027 (estimated)
Completion
Feb 1, 2027 (estimated)
Last update
Aug 27, 2024

Study contacts

SIN-GON KIM
Contact
k50367@korea.ac.kr
8229205890
SIN-GON KIM
principal investigator · Korea University Anam Hospital

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion